Sandbox:risk: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
{{familytree/end}} | {{familytree/end}} | ||
<br> | <br> | ||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | | | | |,|-| A01 | | | | |A01= | |||
<div style="width: 20em; padding:0em;text-align:left"> | |||
* '''INSS stage 1'''<br> | |||
*'''Irrespective of age'''<br> | |||
*'''Irrespective of grade'''<br> | |||
*'''Irrespective of molecular pathway'''</div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | |)|-| B01 | | | | ||B01=<div style="width: 20em; padding:0em;text-align:left"> | |||
*'''INSS stage 2A/2B (>50% resected)'''<br> | |||
*'''Irrespective of age'''<br> | |||
*'''Irrespective of grade'''<br> | |||
*'''''MYCN'' not amplified'''</div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | C01 |-|(| | | | | |C01=<div style="width: 20em; padding:1em;text-align:center">'''Intermediate risk neuroblastoma patients (group 1)'''</div> | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | |)|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | |||
*'''INNS stage 4S'''<br> | |||
*'''<365 days of age'''<br> | |||
*'''Favorable histology'''<br> | |||
*'''DNA index >1'''<br> | |||
*'''''MYCN'' not amplified'''</div>}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | |`|-| C02 | | | | | | |C02=<div style="width: 20em; padding:0em;text-align:left"> | |||
*'''INNS stage 4S'''<br> | |||
*'''<365 days of age'''<br> | |||
*'''Favorable histology'''<br> | |||
*'''DNA index >1'''<br> | |||
*'''''MYCN'' not amplified'''</div>}} | |||
{{familytree/end}} | |||
<br> | |||
{{familytree/end}} | |||
<br> | |||
{{familytree | | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | | | | |,|-| A01 | | | | | | |A01= | |}} | |||
{{familytree | | | | | | | | | |,|-| | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | |)|-| B01 | | | | | | |B01= | | }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | {{familytree | | | | | | C01 |-|(| | | | | | | | | |C01= | | | }} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | |)|-| D01 | | | | | | |D01= | | }} | |||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | |`|-| E01 | | | | | | |E01= | |}} | |||
{{familytree | | | | | | | | | |`|-| | |||
Revision as of 02:23, 10 October 2015
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk neuroblastoma patients |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients (group 1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intermediate risk neuroblastoma patients include:
Group 1
Patients with stage 2A/2B (<50% resected or Bx only) tumor, 0-12 years of age, irrespective of the grade, MYCNnot amplified Patients with stage 3 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified Patients with stage 3 tumor, 1-12 years of age, favorable histology, MYCNnot amplified Patients with symptomatic stage 4S, <365 days of age, favorable histology, DNA index >1, MYCNnot amplified
Group 2
Patients with stage 3 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified Patients with stage 4 tumor, <365 days of age, favorable histology, DNA index >1, MYCN not amplified Patients with stage 4S tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified
Group 3
Patients with stage 4 tumor, <365 days of age, unfavorable histology, DNA index=1, MYCN not amplified Patients with stage 3 tumor, 365-547 days of age, unfavorable histology, MYCN not amplified Patients with stage 4 tumor, 365-547 days of age, favorable histology, DNA index >1, MYCN not amplified